What Is Kynurenic Acid? Normal vs Optimal Range Explained

Kynurenic acid sits at a critical branch point in tryptophan metabolism that determines whether your brain chemistry tilts toward neuroprotection or neuroinflammation. When tryptophan enters the kynurenine pathway—which processes approximately 95 percent of dietary tryptophan, far more than the serotonin pathway—it can be shuttled toward either kynurenic acid (neuroprotective, NMDA receptor antagonist) or quinolinic acid (neurotoxic, NMDA receptor agonist). The CTD maps over 140 compound interactions affecting kynurenine pathway enzymes, reflecting how inflammation, cortisol, nutrient status, and medications influence this critical branch point. When kynurenic acid falls below 0.5 mmol/mol creatinine, the pathway has shifted toward the neurotoxic quinolinic acid branch—a pattern consistently associated with depression, anxiety, cognitive decline, and neuroinflammatory conditions. This shift occurs because the same inflammatory signals that activate the kynurenine pathway preferentially upregulate the enzymes leading to quinolinic acid while leaving kynurenic acid production relatively suppressed. The optimal range of 0.5–2.5 mmol/mol creatinine reflects adequate neuroprotective metabolite production without excessive NMDA receptor blockade.

The kynurenine pathway is uniquely sensitive to inflammatory signaling. Pro-inflammatory cytokines—particularly interferon-gamma and TNF-alpha—activate indoleamine 2,3-dioxygenase (IDO), the enzyme that diverts tryptophan away from serotonin and into the kynurenine pathway. PubMed indexes over 6,800 publications on kynurenic acid, with clinical analyses linking chronic inflammation to a specific pattern: increased total kynurenine pathway flux combined with preferential routing toward quinolinic acid over kynurenic acid. This inflammatory shift explains why depression is so common in chronic inflammatory conditions, autoimmune diseases, and post-infection states—the same inflammation that drives CRP and IL-6 simultaneously reroutes tryptophan metabolism away from both serotonin production and neuroprotective kynurenic acid production toward neurotoxic quinolinic acid accumulation. Conditions such as rheumatoid arthritis, inflammatory bowel disease, and long COVID all demonstrate this pattern, where systemic immune activation translates into measurable changes in kynurenine pathway metabolite ratios that correlate with the severity of neuropsychiatric symptoms.

Exercise produces one of the most striking effects on kynurenic acid levels. Contracting skeletal muscle upregulates kynurenine aminotransferase (KAT), the enzyme that converts kynurenine to neuroprotective kynurenic acid rather than allowing it to proceed toward neurotoxic quinolinic acid. This muscle-mediated pathway shift is one proposed mechanism behind exercise's antidepressant and neuroprotective effects—regular physical activity literally redirects tryptophan metabolism toward the protective branch. B6 (as pyridoxal-5-phosphate) is a required cofactor for KAT, meaning that B6 deficiency can impair kynurenic acid production even when tryptophan and kynurenine substrate are adequate. Individuals who combine regular aerobic exercise with sufficient B6 intake create the strongest conditions for sustained kynurenic acid production. The quinolinic-to-kynurenic acid ratio above 2.0 is increasingly used as a functional marker of neuroinflammatory burden, providing insight into brain health that neither marker delivers alone and guiding targeted interventions ranging from anti-inflammatory protocols to exercise prescriptions.

“Kynurenine pathway metabolites serve as key mediators of exercise-induced mood enhancement, fatigue resistance, and neuroprotection through muscle-dependent conversion of neurotoxic precursors to neuroprotective end products.”

— Tero-Vescan et al., International Journal of Molecular Sciences (2025)